Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Philip Morris seals deal for UK's Vectura despite health group concerns

Published 09/16/2021, 02:18 AM
Updated 09/16/2021, 07:11 AM
© Reuters. FILE PHOTO: Philip Morris International's research and development headquarters are pictured next to the company's cigarette factory in Neuchatel, Switzerland, March 17, 2017. Picture take March 17, 2017. REUTERS/Paritosh Bansal/File Photo

By Pushkala Aripaka and Siddharth Cavale

(Reuters) -Cigarette maker Philip Morris (NYSE:PM) (PMI) clinched its 1.1 billion-pound takeover of asthma inhaler maker Vectura on Thursday, winning the support of the British company's shareholders despite the concerns of health professionals.

Vectura's shareholders decided to take the 165 pence-per-share offer from PMI, with nearly 75% backing the deal.

Buying the London-listed inhaler maker is part of Philip Morris' long term plan to develop "smoke-free" products and switch to being a "broader healthcare and wellness" company.

But it has angered health groups such as Asthma UK and the British Lung Foundation that have questioned whether a tobacco group should own a company that cures the very respiratory illnesses cigarettes cause.

PMI Chief Executive Jacek Olczak has argued that acquiring Vectura is a critical part of his strategy to move the company "Beyond Nicotine".

He told the Telegraph last month that opponents of the deal were "not interested in progress" and accused them of "settling old scores" with the tobacco industry.

Olczak said on Thursday PMI would provide Vectura's scientists with the resources and expertise to reach its goal of generating at least $1 billion in net revenue from "Beyond Nicotine" products by 2025.

In the meantime, Asthma UK and the British Lung Foundation said they have sent a letter urging the government to look into any conflict of interest issues.

The letter was co-signed by 35 charities, public health experts and clinicians.

"There's now a very real risk that Vectura's deal with big tobacco will lead to the cigarette industry wielding undue influence on UK health policy," said Sarah Woolnough, Chief Executive of Asthma UK and the British Lung Foundation.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

"We call on the government to stand by its commitment to the World Health Organization Framework Convention on Tobacco Control to prevent this happening," Woolnough added.

PMI has received regulatory clearances for the deal and following the public tender process, its offer cannot now be withdrawn.

While the company received the 50% threshold to make its offer unconditional, it has not yet reached the 75% of shares it needs to delist Vectura.

PMI said it was extending its offer to Sept 30., to give Vectura shareholders time to accept its proposal.

"Phillip Morris isn't ignoring the elephant; it's making us all take a long hard look. Discomfort is good, it tends to deliver change, but care must be taken that the promised change does come and there are no detours on the journey," AJ Bell financial analyst Danni Hewson said.

($1 = 0.7234 pounds)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.